<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9801">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728805</url>
  </required_header>
  <id_info>
    <org_study_id>0761-010</org_study_id>
    <nct_id>NCT01728805</nct_id>
  </id_info>
  <brief_title>Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL</brief_title>
  <official_title>Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Pharma, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the progression free survival of KW-0761 versus
      vorinostat for subjects with relapsed or refractory CTCL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3 randomized study to compare the progression free survival of subjects with
      relapsed/refractory CTCL who receive KW-0761 versus those who receive vorinostat. Subjects
      who progress on vorinostat will be allowed to cross over to KW-0761 upon progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>pruritis evaluation</measure>
    <time_frame>up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>at the end of cycle 1 (26-28 days), and then every other cycle (cycle 3,5,7,etc.)until progression up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessments</measure>
    <time_frame>up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">317</enrollment>
  <condition>Cutaneous T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>KW-0761</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vorinostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vorinostat 400 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KW-0761</intervention_name>
    <description>1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression</description>
    <arm_group_label>KW-0761</arm_group_label>
    <other_name>mogamulizumab</other_name>
    <other_name>POTELIGEO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <arm_group_label>Vorinostat</arm_group_label>
    <other_name>400 mg orally daily</other_name>
    <other_name>ZOLINZA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and female subjects  ≥ 18 years of age at the time of enrollment, except in
             Japan where subjects must be ≥ 20 years of age at the time of enrollment

          -  Histologically confirmed diagnosis of mycosis fungoides (MF) or Sezary Syndrome (SS)

          -  Stage IB, II-A, II-B, III and IV

          -  Subjects who have progressed following  at least one  prior course of systemic
             therapy. Psoralen plus ultraviolet light therapy (PUVA) is not considered to be a
             systemic therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1 at study
             entry

          -  Resolution of all clinically significant toxic effects of prior cancer therapy to
             grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse
             Events, version 4.0 (NCI-CTCAE, v.4.0)

          -  Adequate hematological, renal and hepatic function

          -  Subjects previously treated with anti-CD4 antibody or alemtuzumab are eligible
             provided their CD4+ cell counts are ≥ 200/mm3

          -  Subjects with mycosis fungoides (MF) and a known history of non-complicated
             staphylococcus infection/colonization are eligible provided they continue to receive
             stable doses of prophylactic antibiotics

          -  Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7
             days of receiving study medication

          -  WOCBP and male subjects and their female partners  of child bearing potential must
             agree to use effective contraception throughout the study

        Exclusion Criteria:

          -  Prior treatment with KW-0761 or vorinostat.

          -  Large cell transformation.

          -  Have had a malignancy in the past two years. However, subjects with non-melanoma skin
             cancers, melanoma in situ, localized cancer of the prostate with current PSA of &lt;0.1
             ng/mL, treated thyroid cancer or cervical carcinoma in situ or ductal/lobular
             carcinoma in situ of the breast with in the past two years may enroll as long as
             there is no current  evidence of disease.

          -  Clinical evidence of central nervous system (CNS) metastasis.

          -  Psychiatric illness, disability or social situation that would compromise the
             subject's safety or ability to provide consent, or limit compliance with study
             requirements.

          -  Significant uncontrolled intercurrent illness

          -  Known or tests positive for human immunodeficiency virus (HIV), human T-cell leukemia
             virus (HTLV-1), hepatitis B or hepatitis C.

          -  Active herpes simplex or herpes zoster. Subjects on prophylaxis for herpes who
             started taking medication at least 30 days prior to study entry, and have no active
             signs of active infection, and whose last active infection was more than 6 months
             ago, may enter the study, and should continue to take the prescribed medication for
             the duration of the study.

          -  Experienced allergic reactions to monoclonal antibodies or other therapeutic
             proteins.

          -  Known active autoimmune disease will be excluded. (For example; Grave's disease;
             systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease; psoriasis).

          -  Is pregnant (confirmed by beta human chorionic gonadotrophin [β-HCG]) or lactating.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitri O. Grebennik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Hakko Kirin Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyowa Hakko Kirin Pharma</last_name>
    <phone>1-609-919-1100</phone>
    <email>clinical.info@kyowa-kirin-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Kaler</last_name>
      <phone>205-502-9967</phone>
      <email>rkaler@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Hughey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baudelio Gutierrez</last_name>
      <phone>310-582-4046</phone>
      <email>bgutierrez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert Eradat, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Illisha Rajasansi</last_name>
      <phone>650-725-1202</phone>
      <email>illisha@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Youn H Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Prewitt</last_name>
      <phone>720-848-0208</phone>
      <email>thomas.prewitt@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine - Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Sellers</last_name>
      <phone>203-737-8358</phone>
      <email>stephanie.sellers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Francine Foss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyce Turba</last_name>
      <phone>813-745-1706</phone>
      <email>elyce.turba@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Lubomir Sokol, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Winship Cancer Institute (Emory University)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Hutchinson-Rzepka</last_name>
      <phone>404-778-3935</phone>
      <email>ahutch7@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Jo Lechowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Cisneros</last_name>
      <phone>312-695-1384</phone>
      <email>cisneros@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Kuzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Petrizzo</last_name>
      <phone>312-563-4001</phone>
      <email>carmen_m_petrizzo@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Tharp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Lengerich</last_name>
      <phone>317-274-8750</phone>
      <email>mlengeri@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Mark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Coleman</last_name>
      <phone>504-988-5135</phone>
      <email>ecoleman@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Boh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center, Department of Medicine, Section of Hem/Onc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juliana Merhaut</last_name>
      <phone>617-638-8280</phone>
      <email>juliana.merhaut@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Adam Lerner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Lantz</last_name>
      <phone>734-936-6936</phone>
      <email>jessicap@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Wilcox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Anderson</last_name>
      <phone>314-747-7399</phone>
      <email>manderso@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Carson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darcie Findley</last_name>
      <phone>603-650-4595</phone>
      <email>darcie.l.findley@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Frederick Lansigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shant Keskinyan</last_name>
      <phone>646-449-1305</phone>
      <email>keskinyv@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Alison Moskowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delcia Rivas</last_name>
      <phone>212-305-2696</phone>
      <email>dr2570@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Adrienne Phillips, M.D., M.P.H.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester School of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Alexander</last_name>
      <phone>585-275-0796</phone>
      <email>carolina_alexander@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Poligone, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zanetta Lamar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joselin Tacastacas</last_name>
      <phone>216-844-5899</phone>
      <email>joselin.tacastacas@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Neil Korman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Messer</last_name>
      <phone>614-366-4470</phone>
      <email>Michelle.Messer@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Pierluigi Porcu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Kirchner</last_name>
      <phone>215-614-0808</phone>
      <email>Kathleen.kirchner@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barbara Pro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue McCann</last_name>
      <phone>412-864-3681</phone>
      <email>mccannsa@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Grandinetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Piggee</last_name>
      <phone>615-875-6120</phone>
      <email>jessica.l.piggee@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>John Greer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.D.Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Wilson, BSN,RN,OCN</last_name>
      <phone>713-563-4655</phone>
      <email>clwilson@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Madeleine Duvic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Pena</last_name>
      <phone>801-213-4233</phone>
      <email>karen.pena@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmad Halwani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Blankenship</last_name>
      <phone>206-288-1172</phone>
      <email>kblanken@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Andrei Shustov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arielle Baim</last_name>
      <phone>414-805-8745</phone>
      <email>abaim@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Sam Hwang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jillian Wells</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ian Lewis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bryone Kuss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter McCallum Cancer Center</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amit Khot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Thorup</last_name>
      <phone>+45 24244900</phone>
      <email>annthoru@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Lars Iversen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amir Khammari</last_name>
      <phone>+33 (0) 240083280</phone>
      <email>amir.khammari@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Dreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halim Bataouche</last_name>
      <phone>+33 1 42 49 93 92</phone>
      <email>halim.bataouche@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Martine Bagot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Villechenoux</last_name>
      <phone>+33 5 57 62 32 27</phone>
      <email>guillaume.villechenoux@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Beylot-Barry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myrtille Le Bouar</last_name>
      <phone>+33 4 78 86 15 96</phone>
      <email>myrtille.le-bouar@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Stephane Dalle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvia Pustal</last_name>
      <phone>+49 621-383-3919</phone>
      <email>s.pustal@dkfz.de</email>
    </contact>
    <investigator>
      <last_name>Claus Klemke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilhelms Universitaet Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Buddendick</last_name>
      <phone>+49 251-835-6558</phone>
      <email>kirsten.buddendick@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Athanasios Tsianakas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Oncology Lorenzo e Ariosto Seràgnoli, University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Tschon</last_name>
      <phone>+39 0516363227</phone>
      <email>marta.tschon2@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Pierluigi Zinzani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renata Ponti</last_name>
      <phone>+39 011 6335858</phone>
      <email>trials.dermo.molinette@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Theresa Fierro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Shinsuke Iida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima-shi</city>
        <state>Fukushima</state>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mikio Otsuka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Osamu Ishikawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maiko Tanaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imamura Bun-in Hospital</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>890-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kentaro Yonekura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hidefumi Wada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu-shi</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kenichi Isoda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kenichi Ishizawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hisashi Uhara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hirakata Hospital</name>
      <address>
        <city>Hirakata-shi</city>
        <state>Osaka</state>
        <zip>571-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Taiki Isei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mamori Tani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yoshiki Tokura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Makoto Sugaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kensei Tobinai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Tama Medical Center</name>
      <address>
        <city>Fuchu-shi</city>
        <state>Tokyo</state>
        <zip>183-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yukihiko Kato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Japanese Foundation for Cancer Research</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kiyohiko Hatake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center - Leids Universitair Medisch Centrum (LUMC)</name>
      <address>
        <city>Leiden</city>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maarten Vermeer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Vega</last_name>
      <phone>+34 917792261</phone>
      <email>evra_83@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Pablo Ortiz-Romero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Baeza Diez</last_name>
      <phone>+34 923291100</phone>
      <email>evadbaeza@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Dolores Caballero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katja Barmettler</last_name>
      <phone>+41 44 255 9485</phone>
      <email>katja.barmettler@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Reinhard Dummer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Worthington</last_name>
      <phone>+44 (0) 1212041602</phone>
      <email>hannah.worthington@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Julia Scarisbrick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys &amp; St. Thomas NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Gomm</last_name>
      <phone>+44 (0)20 7188 7188</phone>
      <phone_ext>51383</phone_ext>
      <email>Nicholas.Gomm@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stephen Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Spence</last_name>
      <phone>+44 (0) 1614468285</phone>
      <email>cathy.spence@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Cowan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>October 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cutaneous T-Cell Lymphoma (CTCL)</keyword>
  <keyword>myocis fungoides (MF)</keyword>
  <keyword>Sezary Syndrome (SS)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
